Last reviewed · How we verify
NCT03211442: MEDIRAD-BRACE
Implications of MEDIcal Low Dose RADiation Exposure - BReast Cancer Acute Coronary Events
trial testing Radiotherapy in Breast Cancer Female in 7,000 participants. Completed in 1 June 2022.
1 August 2020
Quick facts
| Lead sponsor | University Medical Center Groningen |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 7,000 |
| Start date | 1 August 2017 |
| Primary completion | 1 August 2020 |
| Estimated completion | 1 June 2022 |
| Sites | 1 location across Netherlands |
Drugs / interventions tested
- Radiotherapy — full drug profile →
Conditions studied
- Breast Cancer Female — all drugs for Breast Cancer Female →
- Acute Coronary Events — all drugs for Acute Coronary Events →
- Cardiac Complications — all drugs for Cardiac Complications →
Sponsor
University Medical Center Groningen
Who can join
Adults 40 to 75, female only, with Breast Cancer Female or Acute Coronary Events. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
MEDIRAD-BRACE aims to determine the relationship between 3D dose distributions in cardiac structures and the risk of acute coronary events (ACE) and other cardiac complications in breast cancer (BC) patients to develop and externally validate multivariable Normal Tissue Complication Probability (NTCP) models to assess the risk of ACE in individual patients based on cardiac dose metrics in the first 10 years after BC radiotherapy.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
Breast Radiotherapy-Related Cardiotoxicity. When, How, Why. Risk Prevention and Control Strategies.
Díaz-Gavela AA, Figueiras-Graillet L, Luis ÁM, Salas Segura J, et al · · 2021 · cited 32× · PMID 33916644 · DOI 10.3390/cancers13071712 -
Association Between Cardiac Radiation Exposure and the Risk of Arrhythmia in Breast Cancer Patients Treated With Radiotherapy: A Case-Control Study.
Errahmani MY, Locquet M, Spoor D, Jimenez G, et al · · 2022 · cited 31× · PMID 35860581 · DOI 10.3389/fonc.2022.892882 -
Synthetic contrast-enhanced computed tomography generation using a deep convolutional neural network for cardiac substructure delineation in breast cancer radiation therapy: a feasibility study.
Chun J, Chang JS, Oh C, Park I, et al · · 2022 · cited 12× · PMID 35459221 · DOI 10.1186/s13014-022-02051-0 -
Cardiac substructure delineation in radiation therapy - A state-of-the-art review.
Finnegan RN, Quinn A, Booth J, Belous G, et al · · 2024 · cited 4× · PMID 38757728 · DOI 10.1111/1754-9485.13668
Verify or expand the search:
- PubMed search for NCT03211442
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Radiotherapy
Trials testing the same drug.
- NCT07497607 — Reduced Elective Nodal and CTV Dose for HPV+ Oropharyngeal Squamous Cell Carcinoma · Phase 2 · not yet recruiting
- NCT06813664 — ctDNA-Guided CURB for OPD mNSCLC on TKI (CURB-TKI) · Phase 2 · not yet recruiting
- NCT07339774 — Traditional Chinese Medicine Preparation Alleviates Radiotherapy-induced Oral Mucositis in Head and Neck Cancer Patients · Phase 2 · recruiting
- NCT07353671 — Topical Periplaneta Americana-Derived Meilian Fuxin Liquid for Radiation Dermatitis · Phase 2, PHASE3 · recruiting
- NCT07245745 — Prospective Clinical Study Comparing PROMS After Adaptive or Conventional Radiotherapy in Prostate Cancer · NA · recruiting
Other recruiting trials for Breast Cancer Female
Currently open trials in the same condition.
- NCT07505797 — ATUSA Ultrasound Diagnostic Imaging for Breast Lesions Evaluation (AUDIBLE) · recruiting
- NCT07198724 — ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrin · Phase 1, PHASE2 · recruiting
- NCT07331506 — Validation of the Oncoliq Test for the Early Detection of Breast Cancer. · recruiting
- NCT07214883 — UCF MammoChat: Image Repository · recruiting
- NCT07120100 — Transcranial Magnetic Stimulation for Chemotherapy-Induced Peripheral Neuropathy in Breast and Gynecologic Cancer Surviv · NA · recruiting
Other University Medical Center Groningen trials
Trials by the same sponsor.
- NCT06647602 — Thyroid Hormone Replacement After Radio Iodine: Value and Efficacy · not yet recruiting
- NCT06809946 — Feasibility of Fluorescence Imaging With Bevacizumab-800CW During Bronchoscopy · Phase 2 · not yet recruiting
- NCT07527390 — CANagliflozin In DIALysis Patients · Phase 4 · not yet recruiting
- NCT07439237 — Implant-supported Maxillary Overdentures; a 15-years Evaluation · not yet recruiting
- NCT07275437 — Effectiveness and Safety of Uptitration of Guideline Directed MEdical Therapy in Heart Failure With Reduced Ejection Fra · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03211442 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Medical Center Groningen
- Last refreshed: 28 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03211442.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing